Insulin intensification - The rationale and the target

International Journal of Clinical Practice

Volumn 63, Issue SUPPL. 164, 2009, Pages 1-5

  Liebl, A ^a  

^a Center for Diabetes and Metabolism   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; ANTIDIABETIC AGENT;

CLINICAL TRIAL; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; PATIENT SATISFACTION; PRIMARY HEALTH CARE;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT SATISFACTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE;

EID: 73349113997     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02175.x     Document Type: Review

References (27)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 865.
2. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
3. Chen HS, Wu TE, Jap TS et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008 31 : 1927 1932.
4. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008 371 : 1753 1760.
5. Nathan DM, Buse JB, Davidson MB et al., American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 32 : 193 203.
6. Deutsche Diabetes Gesellschaft. Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft. http://www.deutsche-diabetes-gesellschaft.de/redaktion/ mitteilungen/leitlinien/PL-DDG2008-Behandlung-Typ2 (accessed July 2009).
7. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002 287 : 2563 2569.
8. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 2003 290 : 2159 2167.
9. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 2653.
10. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003 26 : 1589 1596.
11. Dandona P, Chaudhuri A, Ghanim H et al. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 2007 99 (Suppl. 15 26.
12. Harris MI, Klein R, Welborn TA et al. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992 15 : 815 819.
13. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roqué i Figuls M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 3). Art. No.: CD002966. doi
14. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 1289.
15. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008 299 : 1561 1573.
16. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 : 2560 2572.
17. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
18. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 360 : 129 139.
19. Reaven P. Risk Factors, Atherosclerosis, and Clinical Events in Type 2 Diabetes (RACED-VADT Ancillary Study). http://webcasts.prous.com/netadmin/ webcast-viewer/Preview.aspx?type=0&lid=4315 (accessed April 2009).
20. Cleary PA, Orchard TJ, Genuth S et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006 55 : 3556 3565. (Pubitemid 44923617)
21. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008 24 : 353 363.
22. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels : International Diabetes Federation, 2005. http://www.idf.org/webdata/ docs/IDF%20GGT2D.pdf (accessed April 2009).
23. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. Endocr Pract 2007 13 (Suppl. 1). http://www.aace.com/pub/pdf/guidelines/DMGuidelines2007.pdf (accessed April 2009).
24. IDF Clinical Guidelines Task Force. Guideline for Management of Postmeal Glucose. Brussels : International Diabetes Federation, 2007. http://www.idf.org/webdata/docs/Guideline-PMG-final.pdf (accessed April 2009).
25. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009 32 : S13 61.
26. National Institute for Health and Clinical Excellence. Type 2 diabetes. NICE Clinical Guideline 66, May 2008. http://www.nice.org.uk/nicemedia/pdf/ CG066NICEGuidelineCorrectedDec08.pdf (accessed April 2009).
27. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003 26 : 881 885.